Cleveland Clinic For Medical Professionals

Phase 3 study finds a fixed-dose combination therapy lowers LDL cholesterol in high-risk patients to levels similar to high-intensity statins.

Obicetrapib-Ezetimibe Combo Therapy Halves LDL Cholesterol Levels Relative to Placebo A fixed-dose combination of obicetrapib and ezetimibe reduces LDL cholesterol in high-risk patients to levels similar to high-intensity statins.